Department of Obstetrics and Gynaecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany.
Gynecol Oncol. 2011 Feb;120(2):302-10. doi: 10.1016/j.ygyno.2010.10.031. Epub 2010 Dec 8.
Gynecologic cancer is still the third leading cause of cancer death among women in the US. Therapeutics employing novel mechanisms of action are therefore urgently needed. Oncolytic viruses (OVs) selectively infecting and replicating in cancer cells have recently attracted considerable interest as promising anti-cancer agents. Here, we provide an overview of different OVs currently being used for virotherapy of gynecologic cancers and discuss challenges and implications for their future development.
Relevant literature obtained from the PubMed database by searching for articles including the terms "oncolytic" or "virus", or "virotherapy" as well as "ovarian" or "cervical" was thoroughly reviewed.
Preclinical in vivo models as well as early clinical trials demonstrated safety and efficacy when targeting gynecologic malignancies with OVs.
While gaining more and more insight into the underlying molecular mechanisms of OVs, virotherapy represents an appealing approach to fight gynecologic malignancies.
妇科癌症仍然是美国女性癌症死亡的第三大主要原因。因此，迫切需要采用新型作用机制的治疗方法。最近，选择性感染和复制癌细胞的溶瘤病毒（OVs）作为有前途的抗癌药物引起了相当大的关注。在这里，我们提供了目前用于妇科癌症病毒治疗的不同 OV 的概述，并讨论了它们未来发展的挑战和影响。
通过在 PubMed 数据库中搜索包含术语“溶瘤”或“病毒”或“病毒疗法”以及“卵巢”或“宫颈”的文章，获得了相关文献，并进行了彻底的回顾。
针对妇科恶性肿瘤的 OV 进行的临床前体内模型和早期临床试验证明了其安全性和有效性。
随着对 OV 潜在分子机制的深入了解，病毒疗法为治疗妇科恶性肿瘤提供了一种有吸引力的方法。
